References in periodicals archive ?
Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone.
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.
Previously, NNDSS did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead, data were collected in aggregate and reported in Table 1 as "Viral hemorrhagic fevers." In response to the need to monitor viral hemorrhagic fevers separately, beginning January 1,2015, cases of Crimean-Congo hemorrhagic fever, Ebola hemorrhagic fever, Guanarito hemorrhagic fever, Junin hemorrhagic fever, Lassa virus infection, Lujo virus infection, Machupo hemorrhagic fever, Marburg fever, and Sabia-associated hemorrhagic fever will be reported separately.
A new diagnostic screen for detection of Ebola Zaire, Ebola Sudan, Marburg, Lassa virus, Rift Valley fever, Crimean-Congo hemorrhagic fever, Hantaan, Seoul, yellow fever, and Kyasanur Forest Disease viruses offers sensitivity and speed by simultaneously considering multiple agents, thereby reducing the time needed for differential diagnosis.
Lassa virus (LASV; species Lassa mammarenavirus, genus Arenaviridae) is the causative agent of Lassa fever.
Emergent BioSolutions and Profectus BioSciences announced a new collaboration with CEPI, the Coalition for Epidemic Preparedness Innovations, under which they will receive up to $36M to advance the development and manufacture of a vaccine against the Lassa virus-an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.
About 80 per cent of people who become infected with Lassa virus have no symptoms.
Add viral hemorrhagic fever caused by Ebola or Marburg viruses, Lassa virus, New World Arenaviruses (Guanarito, Machupo, Junin, Sabia), or Crimean-Congo hemorrhagic fever to the nationally notifiable condition list.
These states have access to the long-established and largest Lassa fever treatment center that has Lassa virus diagnostic capabilities in Nigeria.
The CEPI funding also included support for Inovio's vaccine against the Lassa virus. In collaboration with GeneOne Life Science, Inovio plans to begin a Phase 1/2 study for MERS in the third quarter of this year.